Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Biocides; animal or insect repellents or attractants
Reexamination Certificate
2007-06-05
2007-06-05
Levy, Neil S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Biocides; animal or insect repellents or attractants
C514S557000, C514S642000
Reexamination Certificate
active
10735454
ABSTRACT:
An antiseptic composition useful in destroying the infectivity of infectious proteins such as prions is disclosed. The antiseptic composition is preferably maintained at either a low pH of 4.0 or less or a high pH of 10.0 or more either of which allows for an environment under which the active component (which is preferably sodium dodecyl sulfate) destroys infectivity. The composition may be added to blood, blood products, collagen, tissues and organs prior to transplantation. The composition also may be added to livestock feed to denature any prions in the livestock. Methods of denaturing infectious proteins are also disclosed which method can use but do not require higher temperatures and long period of exposure.
REFERENCES:
patent: 4300905 (1981-11-01), Bleisteiner et al.
patent: 4320086 (1982-03-01), Reiss
patent: 4587329 (1986-05-01), Tomalia et al.
patent: 4806627 (1989-02-01), Wisniewski et al.
patent: 5308611 (1994-05-01), Thompson
patent: 5336432 (1994-08-01), Petchul et al.
patent: 5499979 (1996-03-01), Wong et al.
patent: 5521060 (1996-05-01), Hoenes et al.
patent: 5547576 (1996-08-01), Onishi et al.
patent: 5565186 (1996-10-01), Prusiner et al.
patent: 5578134 (1996-11-01), Lentsch et al.
patent: 5633349 (1997-05-01), Reichl
patent: 5718910 (1998-02-01), Oakes et al.
patent: 5731275 (1998-03-01), Prevost et al.
patent: 5757361 (1998-05-01), Hirshik
patent: 5780288 (1998-07-01), Rohwer
patent: 5808011 (1998-09-01), Gawryl et al.
patent: 5834020 (1998-11-01), Margerum et al.
patent: 5846533 (1998-12-01), Prusiner et al.
patent: 5858326 (1999-01-01), Kislievsky et al.
patent: 5919442 (1999-07-01), Yin et al.
patent: 5977324 (1999-11-01), Prusiner et al.
patent: 6025312 (2000-02-01), Saito et al.
patent: 6096216 (2000-08-01), Shanbrom et al.
patent: 6106773 (2000-08-01), Miekka et al.
patent: 6110908 (2000-08-01), Guthery
patent: 6127448 (2000-10-01), Domb
patent: 6150172 (2000-11-01), Schmerr et al.
patent: 6190650 (2001-02-01), Matthews et al.
patent: 6197207 (2001-03-01), Chapman et al.
patent: 6197935 (2001-03-01), Doillon et al.
patent: 6613728 (2003-09-01), Sirianni et al.
patent: 6627590 (2003-09-01), Sherry et al.
patent: 6780979 (2004-08-01), Deslys
patent: 1244759 (1988-11-01), None
patent: 3229097 (1984-02-01), None
patent: 4331942 (1995-03-01), None
patent: 0 858 797 (1998-08-01), None
patent: WO 93/10227 (1993-05-01), None
patent: WO 93/23432 (1993-11-01), None
patent: WO 95/31466 (1995-11-01), None
patent: WO 97/14404 (1997-04-01), None
patent: WO 97/40861 (1997-11-01), None
patent: WO 97/43649 (1997-11-01), None
patent: WO 97/49774 (1997-12-01), None
patent: WO 98/15297 (1998-04-01), None
patent: WO 98/32334 (1998-07-01), None
patent: WO 98/37411 (1998-08-01), None
patent: WO 99/42102 (1999-08-01), None
patent: WO 99/42487 (1999-08-01), None
patent: WO 00/15239 (2000-03-01), None
patent: WO 00/65344 (2000-11-01), None
patent: WO 00/72851 (2000-12-01), None
patent: WO 01/54736 (2001-08-01), None
West et al : TextBook of Biochemistry Proteins pp. 342-346, 326.
Supattapone et al., “Elimination of prions by branched polyamines and implications of therapeutics”PNAS96(25):14529-14534 (Dec. 7, 1999).
Block, S.S., “Disinfection, Sterilization, and Preservation (Fourth Edition)” 1991, Lea & Febiger, London, GB XP002325193, Chapter 2: Definition of Terms, pp. 18-25.
Castle et al., “Effects of Different Methods of Purification on Aggregation of Scrapie Infectivity”J. Gen. Virol68:225-231 (1987).
Database Embase, Elsevier Science Publishers, Amsterdam, NL: 1998 Dealler, SF, “Transmissable Spongiform encephalopathy: Current and future therapeutic stragegies” XP002325195, Database Acession No. EMB-1998210862 *abstract* & Reviews in Medical Microbiology 1998, United Kingdom, vol. 9, No. 3, 1998, pp. 135-151, ISSN: 0954-139X.
Database Embase, Elsevier Science Publishers, Amsterdam, NL; May 1, 1999, Seman et al., “Prospects for pharmacological treatment of transmissible subactue spongiform encephalopathies” XP002325196, Database accession No. EMB-1999174466 abstract & Revue du Praticien May 1, 1999 France, vol. 49, No. 9, May 1, 1999, pp. 971-975, ISSN: 0035-2640.
Urmoneit et al., “Cationic Lipids (Lipofectamine) and Disturbance of Cellular Cholesterol and aSphingomyelin Distribution Modulates Gamma-Secretase Activity Within Amyloid Precursor Protein In Vitro”Prostaglandins&other Lipid Mediators55:331-343 (1998).
Römpp Chemie Lexikon, 9thedition, pp. 2294, table.
Alpatova, N.M., et al., (1994) “Comparison of Electrochemical Behavior of Heteropolyacids in Solution and Immobilized in a Conducting Polymer Film,” Chemical Abstracts, vol. 121, No. 16.
Anderson, et al., (1996) “Transmission dynamics and epidemiology of BSE in British cattle,” Nature 382: 779-88.
Barry, R.A., et al., (1986) “Monoclonal Antibodies to the Cellular and Scrapie Prion Proteins,” Journal of Infectious Diseases 154:518-521.
Basler, et al., (1986) “Scrapie and Cellular PrP Isoforms Are Encoded by the Same Chromosomal Gene,” Cell, 46:417-28.
Bendheim, et al., (1984) “Antibodies to a Scrapie Prion Protein,” Nature 310:418-421.
Bode, et al., (1985) “Characterization of Antisera Against Scrapie-Associated Fibrils (SAF) from Affected Hamster and Cross-Reactivity with SAF from Scarpie-Affected Mice and from Patients with Creutzfeldt-Jacob Disease,” J. Gen. Virol. 66: 2471-2478.
Bolton, et al., (1982) “Identification of a Protein That Purifies with the Scrapie Prion,” Science 218: 1309-11.
Brown, et al., (1992) “Friendly Fire in Medicine: Hormones, Homografts, and Creutzfeldt-Jakob Disease,” Lancet 340: 24-27.
Bruce, M.E., et al., (1997) “Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent,”Nature,vol. 389:498-501.
Buchanan, et al., (1991) “Mortality, Neoplasia, and Creutzfeldt-Jakob Disease in Patients Treated with Human Pituitary Growth Hormone in the United Kingdom”, BMJ 302:824-828.
Bueler, et al., (1992) “Normal Development and Behavior of Mice Lacking the Neuronal Cell- surface PrP Protein,” Nature 356:577-582.
Carter, et al., (1992) “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment,” Biotechnology 10:163-7.
Cochius, et al., (1990) “Creutzfeldt-Jakob Disease in a Recipient of Human Pituitary-Derived Gonadotrophin,” Aust. N.Z. J. Med. 20:592-593.
Cochius, et al., (1992) “Creutzfeldt-Jakob Disease in a Recipient of Human Pituitary-Derived Gonadotrophin: A Second Case,” J. Neurol. Neurosurg. Psychiatry 55:1094-1095.
Collinge, et al., (1996) “Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease,” Lancet 348: 56.
Combs, et al, (1999) “Indentification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of .beta.-Amyloid and Prion Proteins,” The Journal of Neuroscience, 19(3):928-939.
Cousens, S.N., et al., (1997) “Predicting the CJD epidemic in humans,”Nature,vol. 385-197-198.
Gabizon, et al., (1988) “Immunoaffinity purification and neutralization of scrapie prion infectivity,” Proc. Natl. Acad. Sci. USA, vol. 85, pp. 6617-6621.
Gajdusek, (1977) “Unconventional Viruses and the Origin and Disappearance of Kuru” Science, 197(4307):943-960.
Gajdusek, D.C., et al., (1966) “Experimental transmission of a kuru-like syndrome to chimpanzees,”Nature,vol. 209:794-796.
Gibbs, C.J., Jr., et al., (1968) “Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee,”Science,vol. 161:388-389.
Gibbs, Jr., et al., (1993) “Creutzfeldt-Jakob Disease Infectivity of Growth Hormone Derived from Human Pituitary Glands,” N. Engl. J. Med. 328:358-359.
Gioia et al., (1994) “Conformational Polymorphism of the Amyloidogenic and Neuroto
Prusiner Stanley B.
Supattapone Surachai
Bozicevic Karl
Bozicevic Field & Francis LLP
Levy Neil S.
The Regents of the University of California
LandOfFree
Sodium dodecyl sulfate compositions for inactivating prions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sodium dodecyl sulfate compositions for inactivating prions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sodium dodecyl sulfate compositions for inactivating prions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3827370